MCID: SLV002
MIFTS: 61

Salivary Gland Cancer malady

Categories: Oral diseases, Cancer diseases, Gastrointestinal diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Salivary Gland Cancer

Aliases & Descriptions for Salivary Gland Cancer:

Name: Salivary Gland Cancer 12 52 41 14
Malignant Neoplasm of Salivary Gland 12 29 69
Malignant Tumor of the Major Salivary Gland 12
Malignant Neoplasm of Major Salivary Gland 12
Malignant Neoplasm of Salivary Gland Duct 12
Malignant Tumor of the Salivary Gland 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8850
ICD10 33 C08
ICD9CM 35 142.8
SNOMED-CT 64 187648003
UMLS 69 C0153362

Summaries for Salivary Gland Cancer

MedlinePlus : 41 your salivary glands make saliva - sometimes called spit - and empty it into your mouth through openings called ducts. saliva makes your food moist, which helps you chew and swallow. it helps you digest your food. it also cleans your mouth and contains antibodies that can kill germs. salivary gland cancer is a type of head and neck cancer. it is rare. it may not cause any symptoms, or you could notice a lump in your ear, cheek, jaw, lip, or inside the mouth fluid draining from your ear trouble swallowing or opening the mouth widely numbness, weakness, or pain in your face doctors diagnose salivary gland cancer using a physical exam, imaging tests, and a biopsy. treatment can include surgery, radiation therapy, and/or chemotherapy. nih: national cancer institute

MalaCards based summary : Salivary Gland Cancer, also known as malignant neoplasm of salivary gland, is related to salivary gland cancer, adult and salivary gland cancer, childhood, and has symptoms including halitosis and snoring. An important gene associated with Salivary Gland Cancer is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Bleomycin and Cevimeline have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, testes and lymph node, and related phenotypes are Decreased viability with paclitaxel and cellular

Disease Ontology : 12 An oral cavity cancer that is located in the salivary gland.

Wikipedia : 71 Salivary gland cancer is a cancer that forms in tissues of a salivary gland. The salivary glands are... more...

Related Diseases for Salivary Gland Cancer

Diseases in the Salivary Gland Cancer family:

Salivary Gland Cancer, Adult

Diseases related to Salivary Gland Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 92)
id Related Disease Score Top Affiliating Genes
1 salivary gland cancer, adult 12.3
2 salivary gland cancer, childhood 12.0
3 brooke-spiegler syndrome 11.0
4 mucoepidermoid carcinoma 10.9
5 sublingual gland cancer 10.9
6 parotid gland cancer 10.9
7 pineal region mature teratoma 10.3 EGFR ERBB2
8 facio skeletal genital syndrome rippberger type 10.2 MMP2 MMP9
9 sengers syndrome 10.2 EGFR MET PTEN
10 gallbladder papillomatosis 10.2 AKT1 BIRC5 MMP2
11 thymus adenocarcinoma 10.2 EGFR MMP2 MMP9
12 early myoclonic encephalopathy 10.2 EGFR PPARG PTEN
13 nodular cutaneous amyloidosis 10.1 BIRC5 MMP2 MMP9
14 metagonimiasis 10.1 ERBB2 MET MMP2
15 epididymis adenocarcinoma 10.1 PTEN PTGS2 STAT3
16 reactive arthritis 10.1 EGFR ERBB2 PTGS2
17 cystic lymphangioma 10.1 MMP7 MMP9 PTEN
18 plague 10.1 CASP8 EGFR ERBB2 MMP9
19 acute tricyclic antidepressant poisoning 10.1 MMP2 MMP7 MMP9
20 kleptomania 10.1 MMP2 MMP7 MMP9
21 tinea profunda 10.1 MMP2 MMP7 MMP9
22 statin toxicity 10.1 BIRC5 MMP9 PTGS2
23 dental caries 10.1 AKT1 EGFR ERBB2 MMP2
24 connective tissue benign neoplasm 10.1 AKT1 CASP3 EGFR
25 ovarian brenner tumor 10.1 AKT1 EGFR MET PTEN
26 nasal cavity disease 10.1 AKT1 EGFR ERBB2 MMP2
27 linear porokeratosis 10.1 MMP2 MMP7 MMP9
28 prostatic adenoma 10.1 EGFR ERBB2 PTEN
29 retinal drusen 10.1 MMP2 MMP7 MMP9
30 adult medulloblastoma 10.1 AKT1 CASP3 EGFR PTEN
31 adult astrocytic tumour 10.1 AKT1 EGFR MMP9 PTEN
32 adult neuronal ceroid lipofuscinosis 10.1 MMP2 MMP9 PTGS2
33 thanatophoric dysplasia, type ii 10.1 BIRC5 CASP3 CASP8 MMP2
34 hepatic flexure cancer 10.1 EGFR MMP2 PTEN SERPINB5
35 grade iii astrocytoma 10.1 AKT1 EGFR MMP2 PTEN
36 chondrodysplasia punctata, rhizomelic, type 1 10.1 MMP7 MMP9 PTGS2
37 progesterone-receptor positive breast cancer 10.0 AKT1 EGFR ERBB2 PTGS2
38 glucose-6-phosphate translocase deficiency 10.0 AKT1 EGFR ERBB2 MET PTEN
39 cystadenoma 10.0 AKT1 CASP3 CASP8
40 marginal zone b-cell lymphoma 10.0 CASP8 EGFR MMP2 MMP9 PTEN
41 traumatic brain injury 10.0 CASP3 MMP2 MMP9
42 fallopian tube adenocarcinoma 10.0 CASP3 ERBB2 PTGS2
43 juvenile astrocytoma 10.0 EGFR MMP2 MMP9 PPARG PTEN
44 senile atrophy of choroid 10.0 CASP3 MMP2 MMP7 MMP9
45 hypotrichosis 8 10.0 CASP3 CASP8 MET MMP2 MMP9
46 glucosephosphate isomerase deficiency 10.0 EGFR ERBB2 MMP2 MMP9 PTEN
47 odontotrichoungual-digital-palmar syndrome 10.0 ERBB2 MET PTGS2
48 cutis laxa, autosomal recessive, type ib 9.9 AKT1 CASP3 CASP8 STAT3
49 uvula cancer 9.9 CASP8 EGFR ERBB2 MAML2
50 postmenopausal atrophic vaginitis 9.9 AKT1 CASP3 CASP8

Graphical network of the top 20 diseases related to Salivary Gland Cancer:



Diseases related to Salivary Gland Cancer

Symptoms & Phenotypes for Salivary Gland Cancer

UMLS symptoms related to Salivary Gland Cancer:


halitosis, snoring

GenomeRNAi Phenotypes related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.26 CASP3 EGFR ERBB2
2 Decreased viability with paclitaxel GR00179-A-3 9.26 EGFR
3 Increased cell viability after pRB stimulation GR00230-A-1 8.92 AKT1 EGFR ERBB2 MET

MGI Mouse Phenotypes related to Salivary Gland Cancer:

44 (show all 24)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.5 BIRC5 CASP3 CASP8 EGFR ERBB2 ISL1
2 growth/size/body region MP:0005378 10.49 AKT1 CASP3 CASP8 CRTC1 EGFR ERBB2
3 cardiovascular system MP:0005385 10.48 PPARG PTEN PTGS2 STAT3 TSC22D1 AKT1
4 homeostasis/metabolism MP:0005376 10.47 PTGS2 STAT3 TRAF2 ISL1 MET MMP2
5 immune system MP:0005387 10.43 AKT1 BIRC5 CASP3 CASP8 CRTC1 EGFR
6 hematopoietic system MP:0005397 10.42 AKT1 BIRC5 CASP3 CASP8 CRTC1 EGFR
7 endocrine/exocrine gland MP:0005379 10.41 CRTC1 EGFR ERBB2 ISL1 MET PPARG
8 mortality/aging MP:0010768 10.41 AKT1 BIRC5 CASP3 CASP8 EGFR ERBB2
9 behavior/neurological MP:0005386 10.35 PTEN PTGS2 STAT3 AKT1 CASP3 CRTC1
10 embryo MP:0005380 10.35 AKT1 BIRC5 CASP8 SERPINB5 STAT3 EGFR
11 muscle MP:0005369 10.3 AKT1 CASP3 CASP8 EGFR ERBB2 ISL1
12 digestive/alimentary MP:0005381 10.28 MET MMP7 MMP9 PTEN PTGS2 STAT3
13 adipose tissue MP:0005375 10.27 AKT1 CRTC1 EGFR PPARG PTEN PTGS2
14 integument MP:0010771 10.25 ISL1 MMP9 PPARG PTEN PTGS2 STAT3
15 neoplasm MP:0002006 10.25 MMP9 PPARG PTEN PTGS2 STAT3 AKT1
16 nervous system MP:0003631 10.22 CASP3 CASP8 EGFR ERBB2 ISL1 MET
17 normal MP:0002873 10.15 AKT1 BIRC5 EGFR ERBB2 ISL1 MET
18 craniofacial MP:0005382 10.14 CASP3 EGFR ERBB2 ISL1 MET MMP2
19 liver/biliary system MP:0005370 10.1 AKT1 CASP8 EGFR MET PPARG PTEN
20 renal/urinary system MP:0005367 10.06 TSC22D1 CASP3 CASP8 EGFR ISL1 MET
21 reproductive system MP:0005389 10 AKT1 CASP3 CRTC1 EGFR ERBB2 ISL1
22 respiratory system MP:0005388 9.9 AKT1 CASP3 CASP8 EGFR ERBB2 MET
23 skeleton MP:0005390 9.7 AKT1 CASP3 EGFR ERBB2 ISL1 MMP2
24 vision/eye MP:0005391 9.36 MMP2 MMP7 MMP9 PPARG PTEN PTGS2

Drugs & Therapeutics for Salivary Gland Cancer

Drugs for Salivary Gland Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 282)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved Phase 4 11056-06-7 5360373
2
Cevimeline Approved Phase 4,Phase 3 107233-08-9 83898 25137844
3 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
4 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
5 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1
6 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 1
7 Autonomic Agents Phase 4,Phase 3,Phase 2
8 Cholinergic Agents Phase 4,Phase 3,Phase 2
9
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
10
Cisplatin Approved Phase 3,Phase 1,Phase 2 15663-27-1 84093 441203 2767
11
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
12
Amifostine Approved, Investigational Phase 3,Phase 1,Phase 2 20537-88-6 2141
13
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
14
Pilocarpine Approved Phase 3,Phase 2 54-71-7, 92-13-7 5910
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
16
Fluorouracil Approved Phase 3,Phase 1 51-21-8 3385
17
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
18
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
19
Succinylcholine Approved Phase 3 306-40-1 5314
20
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
21
Doxepin Approved Phase 3 1668-19-5 667477 667468
22
leucovorin Approved, Nutraceutical Phase 3,Phase 1 58-05-9 54575, 6560146 143
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
24
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
25
Iodine Phase 3,Early Phase 1 7553-56-2 807
26 cadexomer iodine Phase 3,Early Phase 1
27 Analgesics Phase 3,Phase 2
28
protease inhibitors Phase 3,Phase 2
29 Gastrointestinal Agents Phase 3,Phase 2
30 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2
31 HIV Protease Inhibitors Phase 3,Phase 2
32 Dermatologic Agents Phase 3,Phase 2
33 Pharmaceutical Solutions Phase 3,Phase 2
34 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
35 Protective Agents Phase 3,Phase 1,Phase 2
36 Anti-Inflammatory Agents Phase 3,Phase 2
37 Liver Extracts Phase 3,Phase 2,Phase 1
38 Radiation-Protective Agents Phase 3,Phase 1,Phase 2
39 Antimetabolites Phase 3,Phase 1,Phase 2
40 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
41 Antimitotic Agents Phase 3,Phase 1,Phase 2
42 Antirheumatic Agents Phase 3,Phase 2
43 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
44 Fluorides Phase 3,Phase 1,Phase 2
45 pancreatic polypeptide Phase 3,Phase 1
46 Mitogens Phase 3,Phase 2,Phase 1
47 Adjuvants, Anesthesia Phase 3
48 Folic Acid Antagonists Phase 3,Phase 1
49 Narcotics Phase 3
50 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 310)
id Name Status NCT ID Phase
1 Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer Completed NCT00198263 Phase 4
2 Effects of Mucoprotective Product on Xerostomia Completed NCT01316393 Phase 4
3 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4
4 A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Completed NCT02049112 Phase 4
5 A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients Recruiting NCT02948699 Phase 4
6 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
7 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
8 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3
9 Hyperbaric Oxygen - a New Treatment Modality in Patients With Radiation Damaged Salivary Gland Tissue Unknown status NCT01606644 Phase 3
10 Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia Unknown status NCT00081029 Phase 3
11 Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients Completed NCT00168181 Phase 3
12 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3
13 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
14 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
15 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
16 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3
17 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3
18 Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00003139 Phase 3
19 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
20 Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas Completed NCT00158691 Phase 3
21 A Trial Looking at Treating Dry Mouth After Radiotherapy for Head and Neck Cancer Completed NCT02941276 Phase 3
22 The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's Syndrome Completed NCT01414790 Phase 3
23 Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer Recruiting NCT02048254 Phase 3
24 Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors Recruiting NCT02998385 Phase 3
25 Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma Recruiting NCT01874587 Phase 3
26 Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? Recruiting NCT01837745 Phase 3
27 Parotid-gland Stem-cell Sparing Intensity-modulated Radiotherapy Recruiting NCT01955239 Phase 3
28 Impact of Selective Radiation Dose Escalation and Tumour Hypoxia Status on Locoregional Tumour Control After Radiochemotherapy of HNT Recruiting NCT01212354 Phase 3
29 Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome? Recruiting NCT01504555 Phase 3
30 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3
31 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Active, not recruiting NCT01156142 Phase 3
32 Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer Active, not recruiting NCT01141231 Phase 3
33 Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia Active, not recruiting NCT01266044 Phase 3
34 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3
35 Activity of Sorafenib in Salivary Gland Cancer Unknown status NCT01703455 Phase 2
36 CO(Mbined Therapy of Malignant) S(Alivary Gland tu)M(Ours With)I(MRT and) c(Arbon Ions): COSMIC Unknown status NCT01154270 Phase 2
37 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2
38 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2
39 Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer Unknown status NCT00003489 Phase 2
40 Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00022217 Phase 2
41 Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Unknown status NCT00052611 Phase 2
42 Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy Unknown status NCT00003856 Phase 2
43 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
44 Treatment of Radiation-induced Fibrosis in the Upper Aerodigestive Tract Cancer by a Combination of Pentoxifylline-tocopherol and Hyperbaric Oxygen Unknown status NCT01822405 Phase 2
45 Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Unknown status NCT00652613 Phase 2
46 A Study of Intensity-modulated Radiotherapy in Patients With Squamous Cell Carcinoma of Unknown Primary (SCCUP) of the Head and Neck Unknown status NCT02112344 Phase 1, Phase 2
47 Hypnosis for Treating Xerostomia Following Radiotherapy in Head & Neck Cancer Patients Unknown status NCT00408759 Phase 2
48 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2
49 Iressa Study in Patients With Salivary Gland Cancer Completed NCT00509002 Phase 2
50 Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Completed NCT00045669 Phase 2

Search NIH Clinical Center for Salivary Gland Cancer

Genetic Tests for Salivary Gland Cancer

Genetic tests related to Salivary Gland Cancer:

id Genetic test Affiliating Genes
1 Salivary Gland Neoplasm 29

Anatomical Context for Salivary Gland Cancer

MalaCards organs/tissues related to Salivary Gland Cancer:

39
Salivary Gland, Testes, Lymph Node, Breast, Myeloid, Liver, Testis

The Foundational Model of Anatomy Ontology organs/tissues related to Salivary Gland Cancer:

18
The Salivary Gl

Publications for Salivary Gland Cancer

Articles related to Salivary Gland Cancer:

(show top 50) (show all 120)
id Title Authors Year
1
High-grade histology as predictor of early distant metastases and decreased disease-free survival in salivary gland cancer irrespective of tumor subtype. ( 26841273 )
2016
2
Unmet needs for patients with salivary gland cancer. ( 27377424 )
2016
3
Cytomegalovirus induces Interleukin-6 mediated inflammatory response in salivary gland cancer. ( 28039719 )
2016
4
Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature. ( 28006087 )
2016
5
(A+)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice. ( 27670669 )
2016
6
ID1 Controls Aggressiveness of Salivary Gland Cancer Cells via Crosstalk of IGF and AKT Pathways. ( 27466488 )
2016
7
Targeting ID2 expression triggers a more differentiated phenotype and reduces aggressiveness in human salivary gland cancer cells. ( 27364596 )
2016
8
Incidence and risk factors of late recurrence in patients with salivary gland cancer. ( 27960047 )
2016
9
The MMP-2 and MMP-9 promoter polymorphisms and susceptibility to salivary gland cancer. ( 27569079 )
2016
10
Outcomes and prognostic factors in modern era management of major salivary gland cancer. ( 26033470 )
2015
11
An epidemiological evaluation of salivary gland cancer in the Netherlands (1989-2010). ( 25454260 )
2015
12
Diagnostic utility of phosphorylated signal transducer and activator of transcription 5 immunostaining in the diagnosis of mammary analogue secretory carcinoma of the salivary gland: A comparative study of salivary gland cancers. ( 26252941 )
2015
13
Convallaria keiskei as a novel therapeutic alternative for salivary gland cancer treatment by targeting myeloid cell leukemia-1. ( 25914292 )
2015
14
Increased risk of salivary gland cancer among women with a previous cancer diagnosis. ( 25581457 )
2015
15
Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer. ( 26661925 )
2015
16
Salivary gland cancer risk and BRCA gene mutations may be linked, study finds. ( 25577819 )
2014
17
The Impact of Demographic and Socioeconomic Factors on Major Salivary Gland Cancer Survival. ( 24647644 )
2014
18
Racial and Ethnic Disparities in Salivary Gland Cancer Survival. ( 24744112 )
2014
19
Overview of major salivary gland cancer surgery in Ontario (2003A?2010). ( 25492404 )
2014
20
Salivary Gland Cancer in BRCA-Positive Families : A Retrospective Review. ( 25257187 )
2014
21
Retracted: the oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac. ( 25610927 )
2014
22
Familial predisposition for salivary gland cancer in Finland. ( 24701124 )
2014
23
Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. ( 23242174 )
2013
24
The Justy mutant mouse strain produces a spontaneous murine model of salivary gland cancer with myoepithelial and basal cell differentiation. ( 23608756 )
2013
25
Antitumour effect of valproic acid against salivary gland cancer in vitro and in vivo. ( 24398788 )
2013
26
Risk of salivary gland cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. ( 22836059 )
2013
27
Expression and function of CXCR4 in human salivary gland cancers. ( 22847686 )
2013
28
Predictors of cervical lymph node metastasis in salivary gland cancer. ( 23780687 )
2013
29
The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases. ( 23611358 )
2013
30
Targeting Id1 reduces proliferation and invasion in aggressive human salivary gland cancer cells. ( 23517130 )
2013
31
Salivary gland cancer stem cells. ( 23810400 )
2013
32
Salivary gland cancer: an update on present and emerging therapies. ( 23714518 )
2013
33
WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer. ( 22399636 )
2012
34
Oral cavity, pharyngeal and salivary gland cancer: disparities in ethnicity-specific incidence among the London population. ( 22521261 )
2012
35
Prognostic significance of RB1-inducible coiled-coil 1 in salivary gland cancers. ( 21717524 )
2012
36
EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. ( 22154363 )
2012
37
Probing the role of mesenchymal stem cells in salivary gland cancer on biomimetic microdevices. ( 22499505 )
2012
38
The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. ( 22445095 )
2012
39
Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. ( 22240798 )
2012
40
Predictive index for lymph node management of major salivary gland cancer. ( 22539053 )
2012
41
Recurrent salivary gland cancer. ( 22215326 )
2012
42
Paediatric salivary gland cancer in Finland. ( 22721526 )
2012
43
Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer. ( 21563549 )
2011
44
Second primaries after major salivary gland cancer. ( 21493280 )
2011
45
Multi-modality curative treatment of salivary gland cancer liver metastases with drug-eluting bead chemoembolization, radiofrequency ablation, and surgical resection: a case report. ( 21867491 )
2011
46
Salivary gland cancer in patients younger than 30 years. ( 21500170 )
2011
47
A comprehensive analysis of parotid and salivary gland cancer: worse outcomes for male gender. ( 20189602 )
2011
48
Cytoplasmic expression of survivin is an independent predictor of poor prognosis in patients with salivary gland cancer. ( 21083600 )
2010
49
Expression of matrix metalloproteinase-1, -7, -9, -13, Ki-67, and HER-2 in epithelial-myoepithelial salivary gland cancer. ( 19902536 )
2010
50
A prognostic index for predicting lymph node metastasis in minor salivary gland cancer. ( 19386433 )
2010

Variations for Salivary Gland Cancer

Expression for Salivary Gland Cancer

Search GEO for disease gene expression data for Salivary Gland Cancer.

Pathways for Salivary Gland Cancer

Pathways related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 106)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 AKT1 BIRC5 CASP3 CASP8 EGFR ERBB2
2
Show member pathways
13.95 AKT1 CASP3 CASP8 EGFR ERBB2 MET
3
Show member pathways
13.94 AKT1 CASP3 CASP8 EGFR MET MMP2
4
Show member pathways
13.8 AKT1 BIRC5 EGFR ERBB2 MET MMP2
5
Show member pathways
13.58 AKT1 EGFR ERBB2 MET MMP2 MMP9
6
Show member pathways
13.49 AKT1 CASP3 EGFR MMP2 MMP7 MMP9
7
Show member pathways
13.49 AKT1 CASP3 EGFR ERBB2 MET PTEN
8
Show member pathways
13.38 AKT1 CASP3 CASP8 EGFR ERBB2 MET
9
Show member pathways
13.37 AKT1 BIRC5 CASP3 EGFR ERBB2 MET
10
Show member pathways
13.35 AKT1 CASP3 CASP8 EGFR ERBB2 MET
11
Show member pathways
13.09 AKT1 EGFR ERBB2 MET MMP2 MMP9
12
Show member pathways
13 AKT1 BIRC5 CASP3 CASP8 MMP9 PTEN
13
Show member pathways
12.98 AKT1 EGFR ERBB2 MET PTEN STAT3
14
Show member pathways
12.98 AKT1 EGFR ERBB2 MET PTEN PTGS2
15
Show member pathways
12.97 AKT1 CASP3 CASP8 EGFR MET TRAF2
16
Show member pathways
12.95 AKT1 CASP3 CASP8 MMP9 TRAF2
17
Show member pathways
12.89 AKT1 BIRC5 CASP3 CASP8 TRAF2
18
Show member pathways
12.88 AKT1 CASP3 ERBB2 MET PTEN PTGS2
19
Show member pathways
12.87 AKT1 CASP3 CASP8 STAT3 TRAF2
20
Show member pathways
12.87 AKT1 CASP3 CASP8 EGFR MMP2 MMP9
21
Show member pathways
12.86 AKT1 BIRC5 PTEN STAT3 TRAF2
22
Show member pathways
12.8 AKT1 EGFR ERBB2 MET PTEN
23 12.78 AKT1 CASP3 CASP8 EGFR TRAF2
24
Show member pathways
12.74 AKT1 CASP3 EGFR STAT3 TRAF2
25
Show member pathways
12.68 AKT1 BIRC5 EGFR ERBB2 MMP2 STAT3
26
Show member pathways
12.58 AKT1 EGFR ERBB2 MET PTEN
27
Show member pathways
12.56 AKT1 CASP3 ERBB2 PTEN STAT3
28
Show member pathways
12.53 AKT1 CASP3 CASP8 EGFR ERBB2 MET
29
Show member pathways
12.49 AKT1 BIRC5 MET PTEN STAT3
30
Show member pathways
12.47 AKT1 CASP3 CASP8 EGFR ERBB2 MMP2
31
Show member pathways
12.44 CASP3 CASP8 PTEN SERPINB5
32
Show member pathways
12.41 AKT1 EGFR ERBB2 PPARG PTGS2
33 12.39 CASP3 EGFR ERBB2 MET MMP9 PTEN
34
Show member pathways
12.38 AKT1 EGFR ERBB2 STAT3
35
Show member pathways
12.38 AKT1 BIRC5 CASP3 EGFR ERBB2 PTEN
36
Show member pathways
12.36 AKT1 CASP3 CASP8 TRAF2
37 12.36 CASP3 CASP8 STAT3 TRAF2
38
Show member pathways
12.35 AKT1 CASP3 PPARG STAT3 TRAF2
39
Show member pathways
12.35 AKT1 CASP3 CASP8 PTGS2 STAT3
40
Show member pathways
12.34 AKT1 CASP3 CASP8 TRAF2
41
Show member pathways
12.33 AKT1 CASP3 CASP8 PTEN
42 12.33 BIRC5 CASP3 CASP8 SERPINB5 TRAF2
43
Show member pathways
12.31 AKT1 CASP3 CASP8 MMP9 PTGS2 STAT3
44 12.27 AKT1 EGFR ERBB2 PTEN STAT3
45
Show member pathways
12.26 AKT1 CASP3 EGFR ERBB2 MET PTEN
46 12.24 AKT1 CASP3 CASP8 EGFR PTEN
47 12.23 AKT1 CASP3 EGFR ERBB2 MET MMP2
48
Show member pathways
12.22 AKT1 EGFR ERBB2 PTEN STAT3
49
Show member pathways
12.2 AKT1 CASP3 CASP8 TRAF2
50 12.19 AKT1 CASP3 CRTC1 STAT3

GO Terms for Salivary Gland Cancer

Cellular components related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.7 AKT1 BIRC5 CASP3 CASP8 CRTC1 ISL1
2 membrane raft GO:0045121 9.56 CASP3 CASP8 EGFR TRAF2
3 cytoplasm GO:0005737 9.53 AKT1 BIRC5 CASP3 CASP8 CRTC1 EGFR
4 death-inducing signaling complex GO:0031264 9.16 CASP3 CASP8

Biological processes related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

(show all 48)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.95 AKT1 EGFR ERBB2 MMP9
2 cell proliferation GO:0008283 9.95 AKT1 EGFR ERBB2 MET PTEN STAT3
3 heart development GO:0007507 9.93 CASP3 ERBB2 ISL1 PPARG PTEN
4 negative regulation of apoptotic process GO:0043066 9.91 AKT1 BIRC5 CASP3 EGFR MMP9 PTEN
5 cellular response to insulin stimulus GO:0032869 9.88 AKT1 PPARG PTEN
6 positive regulation of apoptotic process GO:0043065 9.88 AKT1 CASP3 MMP9 PPARG PTEN PTGS2
7 movement of cell or subcellular component GO:0006928 9.87 PTGS2 SERPINB5 STAT3
8 positive regulation of cell growth GO:0030307 9.87 AKT1 EGFR ERBB2
9 extracellular matrix disassembly GO:0022617 9.87 MMP2 MMP7 MMP9
10 memory GO:0007613 9.86 CRTC1 PTEN PTGS2
11 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.86 AKT1 PPARG PTEN TRAF2
12 collagen catabolic process GO:0030574 9.85 MMP2 MMP7 MMP9
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 AKT1 EGFR PTGS2
14 cellular response to growth factor stimulus GO:0071363 9.84 AKT1 EGFR ERBB2
15 negative regulation of neuron death GO:1901215 9.83 AKT1 STAT3 TRAF2
16 learning or memory GO:0007611 9.83 CASP3 EGFR PTEN
17 aging GO:0007568 9.83 AKT1 MMP7 PTEN PTGS2 STAT3
18 embryo implantation GO:0007566 9.82 MMP2 MMP9 PTGS2
19 cellular response to epidermal growth factor stimulus GO:0071364 9.81 AKT1 EGFR ERBB2
20 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.81 AKT1 EGFR ERBB2 MET
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 AKT1 EGFR PTGS2
22 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.8 CASP3 CASP8 PPARG TRAF2
23 execution phase of apoptosis GO:0097194 9.79 AKT1 CASP3 CASP8
24 positive regulation of vasoconstriction GO:0045907 9.79 AKT1 EGFR PTGS2
25 cellular response to reactive oxygen species GO:0034614 9.76 AKT1 EGFR MMP9
26 cellular response to organic cyclic compound GO:0071407 9.76 AKT1 CASP3 CASP8 STAT3
27 cellular response to cadmium ion GO:0071276 9.75 AKT1 EGFR MMP9
28 response to tumor necrosis factor GO:0034612 9.74 CASP3 CASP8 PTGS2
29 positive regulation of DNA binding GO:0043388 9.72 ISL1 MMP9 PPARG
30 phosphatidylinositol-mediated signaling GO:0048015 9.72 AKT1 EGFR ERBB2 MET PTEN
31 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.7 CASP8 TRAF2
32 regulation of necroptotic process GO:0060544 9.7 CASP8 TRAF2
33 negative regulation of cell size GO:0045792 9.69 AKT1 PTEN
34 cellular response to leptin stimulus GO:0044320 9.68 PTEN STAT3
35 death-inducing signaling complex assembly GO:0071550 9.68 CASP8 TRAF2
36 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.67 AKT1 EGFR
37 response to cobalt ion GO:0032025 9.66 CASP3 CASP8
38 cellular response to mechanical stimulus GO:0071260 9.65 AKT1 CASP8 EGFR MMP7 PTGS2
39 response to organic cyclic compound GO:0014070 9.63 CASP3 EGFR PPARG PTEN PTGS2 STAT3
40 cellular response to decreased oxygen levels GO:0036294 9.62 AKT1 PTEN
41 response to UV-A GO:0070141 9.61 AKT1 EGFR
42 positive regulation of I-kappaB phosphorylation GO:1903721 9.6 AKT1 TRAF2
43 response to estradiol GO:0032355 9.43 CASP3 CASP8 EGFR PTEN PTGS2 STAT3
44 response to organic substance GO:0010033 9.1 AKT1 CASP3 PPARG PTEN PTGS2 STAT3
45 apoptotic process GO:0006915 10.15 AKT1 BIRC5 CASP3 CASP8 PTEN TRAF2
46 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.13 AKT1 CRTC1 EGFR ISL1 MAML2 MET
47 positive regulation of cell proliferation GO:0008284 10.07 BIRC5 EGFR ISL1 PTEN PTGS2 STAT3
48 response to drug GO:0042493 10.04 CASP3 PPARG PTEN PTGS2 STAT3

Molecular functions related to Salivary Gland Cancer according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.8 AKT1 EGFR PTEN STAT3 TRAF2
2 enzyme binding GO:0019899 9.7 AKT1 BIRC5 EGFR PPARG PTEN PTGS2
3 identical protein binding GO:0042802 9.65 AKT1 BIRC5 CASP8 EGFR ERBB2 MMP9
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.63 EGFR ERBB2 MET
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.54 EGFR ERBB2 MET
6 cysteine-type endopeptidase activity involved in execution phase of apoptosis GO:0097200 9.49 CASP3 CASP8
7 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.48 EGFR ERBB2
8 cysteine-type endopeptidase activity involved in apoptotic process GO:0097153 9.43 CASP3 CASP8
9 nitric-oxide synthase regulator activity GO:0030235 9.32 AKT1 EGFR
10 protein phosphatase binding GO:0019903 9.1 EGFR ERBB2 MET PPARG STAT3 TRAF2
11 protein binding GO:0005515 10.23 AKT1 BIRC5 CASP3 CASP8 CRTC1 EGFR

Sources for Salivary Gland Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....